Bard’s Davol subsidiary, located in Cranston, Rhode Island, will begin marketing the line immediately.
The Sepramesh IP product incorporates a polypropylene mesh with a layer of Sepra material on one side. The product combines the strength of a permanent implant with a bioresorbable hydrogel barrier to minimize tissue attachment to the mesh. This protective coating is absorbed over time, resulting in a permeable, flexible hernia repair.
Timothy Ring, chairman and CEO of Bard, said: “The Sepramesh IP product accelerates our entry into this space and represents a good growth opportunity for 2008 and beyond.”